© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 14, 1034-1035,
July 16, 2003
© 2003 Oxford University Press
NEWS |
Out of Fashion: Non-Proteomic Research Vying for Attention
| The first 150 words of the full text of this article appear below. |
Although some claimed it could not be done, industry scientists reported recently in Cancer Immunology, Immunotherapy that they have identified a novel cell-surface antigen on small-cell lung cancer cells, marking one of the first—if not the first—unique molecular target to be found on these tumors, which account for about 20% of lung cancers.
And the news gets even better. The team found that, when bound by an antibody, this still nameless antigen is then internalized by the tumor cell, suggesting that it might be an ideal port of entry for a deadly immunotoxin to enter and kill the cancer cells. What’s more, they also found that this antigen sheds into the blood of people with established and possibly developing small-cell lung cancer, meaning it could have important implications for future diagnostic and prevention strategies.
As intriguing as this finding sounds, don’t expect to find the antigen listed on the CancerTrials
Cryptic Antigens
Addition By Subtraction
Out of Money